<DOC>
	<DOCNO>NCT01233505</DOCNO>
	<brief_summary>This phase I trial study side effect best dose veliparib give together capecitabine oxaliplatin treat patient advance solid tumor . Veliparib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , capecitabine oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving veliparib together capecitabine oxaliplatin may kill tumor cell .</brief_summary>
	<brief_title>Veliparib , Oxaliplatin , Capecitabine Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine dose limit toxicity ( DLTs ) maximum tolerate dose ( MTD ) ABT-888 ( veliparib ) combination oxaliplatin capecitabine advance solid tumor . SECONDARY OBJECTIVES : I . To evaluate pharmacokinetics ABT-888 , oxaliplatin , capecitabine administer concomitantly . II . To evaluate safety tolerability ABT-888 combination capecitabine oxaliplatin . III . To assess evidence anti-tumor activity combination , per tumor measurement use RECIST criterion , patient . TERTIARY OBJECTIVES : I . To assess inhibition poly ( ADP-ribose ) polymerase ( PARP ) peripheral blood mononuclear cell secondary treatment ABT-888 . II . To determine pharmacokinetics ABT-888 combination oxaliplatin capecitabine relation treatment side effect . OUTLINE : This dose-escalation study veliparib . Patients receive veliparib orally ( PO ) twice daily capecitabine PO twice daily 1-7 15-21 , oxaliplatin intravenously ( IV ) 2 hour day 1 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo blood urine sample collection baseline periodically study pharmacokinetic poly ( ADP-ribose ) polymerase ( PARP ) inhibition study . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Cystadenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Histologically cytologically confirm solid tumor fulfill ≥ 1 follow criterion : BRCA1/2 mutation BRCArelated malignancy Patients without know BRCA mutation must probability harbor BRCA gene mutation assess BRCAPRO computer program Patients probability genetic mutation ≥ 20 % BRCA mutation base nonMyriad test , must formal BRCA test Myriad Genetic Laboratories Patients know deleterious BRCA 1 2 mutation mutation uncertain significance Patients refuse BRCA test allow unless another acceptable histology First secondline metastatic colorectal cancer Anyline metastatic mucinous ovarian cancer Any line metastatic gastrointestinal malignancy oxaliplatin show activity ( i.e. , gastric pancreatic adenocarcinoma ) Patients uncontrolled CNS metastasis eligible ; patient CNS metastasis treat stable &gt; 3 month eligible ; patient must steroid treatment prior study enrollment Measurable disease Patients ovarian cancer pretreatment CA 125 level least twice upper limit normal allow ECOG performance status ( PS ) 02 ( Karnofsky 60100 % ) Life expectancy &gt; 3 month ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( ≤ 5 time ULN patient liver metastasis ) Creatinine ≤ 1.5 time ULN OR creatinine clearance ≥ 60 mL/min Fertile patient must use adequate contraception ( i.e. , hormonal , barrier method birth control , abstinence ) Not pregnant nursing Negative pregnancy test No history allergic reaction attribute compound similar chemical biologic composition veliparib agent use study No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness and/or social situation would limit compliance study requirement No history positive serology hepatitis A , B , C , liver disease , form hepatitis cirrhosis Patients active seizure history seizure ineligible No condition impair ability swallow retain veliparib capsule , include follow : Gastrointestinal tract disease result inability take oral medication requirement IV alimentation Prior surgical procedure affect absorption Active peptic ulcer disease No malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , ulcerative colitis , inflammatory bowel disease , partial complete small bowel obstruction No peripheral neuropathy ≥ grade 2 No prolong QTC &gt; 450 msec ( male ) QTC &gt; 470 ( female ) No concurrent combination antiretroviral therapy HIVpositive patient Recovered adverse event prior therapy prior surgical procedure Patients chronic grade 1 2 adverse event expect improve allow investigator 's discretion At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) At least 4 week since prior radiotherapy &gt; 35 % marrow irradiation Prior fluoropyrimidine allow Prior veliparib allow provided part single limiteddosing study , phase 0 study Prior capecitabine allow provided patient tolerate 3500 mg/m² 7 day 14 day No prior investigational agent No prior oxaliplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>